BioLife Solutions, Inc. — Form 8-K Summary
Reporting event: October 6, 2026. This filing reports completion of Repligen Corporation’s acquisition of BioLife Solutions; it is a transaction update, not a periodic financial-results filing.
Business context and transaction
Two mergers completed on October 6, 2026. BioLife first became a direct, wholly owned subsidiary of Repligen and then merged into Repligen subsidiary Bravo Merger Sub II, LLC, which survived as a wholly owned subsidiary of Repligen.
For each eligible BioLife share, holders became entitled to $11.25 in cash plus 0.1442 Repligen common shares. Fractional Repligen shares were paid in cash. Properly perfected, unwithdrawn dissenting shares are instead subject to appraisal rights under Delaware law. BioLife equity awards were accelerated, vested or settled under the merger terms and converted into the merger consideration.
Financial metrics and changes
This 8-K does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating-performance figures, and does not provide a clear aggregate transaction value. The market value of the stock component depends on Repligen’s share price.
The principal change is a change of control: BioLife became wholly owned by Repligen. BioLife ceased to exist as a separate legal entity, its common stock ceased to be listed on Nasdaq, and the company stated that it intends to file to terminate its Exchange Act registration and reporting obligations.
Governance and stockholder vote
BioLife’s directors and named executive officers resigned at the effective time; Merger Sub 1’s directors and officers became BioLife’s directors and officers before the second merger. BioLife’s certificate of incorporation and bylaws were amended and restated.
At the October 5, 2026 special meeting, holders representing 83.79% of outstanding shares were present or represented by proxy. The merger agreement was adopted with 40,910,337 votes for, 83,451 against, and 807 abstentions. The advisory merger-compensation proposal passed; the adjournment proposal was moot because the merger agreement had sufficient votes.
Outlook, risks, and unusual items
The filing provides no standalone BioLife guidance or post-merger outlook. It notes that merger-agreement representations and warranties were made for purposes of allocating risk between the parties and should not be relied on as establishing factual matters. The filing also reports accelerated vesting and settlement of outstanding BioLife options, restricted stock units, performance-based units, and restricted stock awards.
Important facts for investors to verify
- Confirm the merger consideration received, including the applicable Repligen share conversion and cash-in-lieu treatment for fractional shares.
- Review the merger agreement and proxy statement for detailed transaction terms, award treatment, and any relevant conditions or disclosures.
- Check the status of BioLife’s Nasdaq delisting and its planned Form 25 and Form 15 filings.
- Consult Repligen’s filings for the combined company’s financial results, integration plans, and outlook; this 8-K does not provide them.